

PCORI's Newly Mandated Research Priorities: Summary of Current Activities

Type of Opportunity	Opportunity Description	Key Dates
<p>The Broad PCORI Funding Announcements – Cycle 3 2020 is a call for investigator-initiated proposals for patient-centered comparative effectiveness research (CER), including those in two special emphasis topics—maternal morbidity and mortality (MMM) and individuals with intellectual and developmental disabilities (IDD).</p>	<p>Within this funding announcement, up to \$30 million is set aside for each of the two special emphasis topics:</p> <ol style="list-style-type: none"> 1. Studies that address barriers in access to and continuity of patient-centered maternal care; particularly for populations who are likely to experience the most significant disparities in care and/or outcomes (e.g., African Americans; Native American/Alaska Natives; and/or women living in rural areas). 2. Studies focused on improving the transition from pediatric to adult healthcare for individuals with intellectual and/or developmental disabilities. This may include the continuation of patient-centered primary and specialty care. <p>Applicants submitting proposals that are responsive to either special emphasis area may seek approval at the Letter of Intent stage for budgets of up to \$10 million in direct costs.</p> <p>All other proposals in response to this announcement may request:</p> <ul style="list-style-type: none"> • Up to \$3 million in direct costs over a 3-year study period • Up to \$5 million in direct costs over a 5-year study period 	<ul style="list-style-type: none"> • September 1, 2020: Online system opened • September 15, 2020: Applicant town hall • September 29, 2020: Deadline for Letters of Intent • January 12, 2021: Application deadline • July 2021: Awards announced

Type of Opportunity	Opportunity Description	Key Dates
<p>The Capacity Building funding mechanism for the Eugene Washington PCORI Engagement Awards Program supports communities in increasing ability to participate across all phases of the patient-centered outcomes research/comparative clinical effectiveness research (PCOR/CER) process.</p> <p>This Program is for research support and does not fund research studies.</p>	<p>The current funding cycle under this mechanism welcomes projects with an explicit focus on maternal morbidity and mortality or intellectual and developmental disabilities. However, proposals for this funding are not limited to these two topics.</p> <p>Individual awards may be made in an amount up to \$250,000 in total costs (direct and indirect) and the maximum project period is 24 months.</p>	<ul style="list-style-type: none"> ● September 1, 2020: Online system opened ● October 1: Deadline for letters of Inquiry (LOI) ● Full proposals are invitation only and are due 40 calendar days after LOI approval ● June 1, 2021: Earliest project start date
<p>The Stakeholder Convening Support funding mechanism for the Eugene Washington PCORI Engagement Awards Program offers funding for multi-stakeholder convenings, meetings, and conferences that align with PCORI's mission and facilitate expansion of PCOR/CER through collaboration around such efforts.</p> <p>This Program is for research support and does not fund research studies.</p>	<p>The current funding cycle under this mechanism welcomes projects with an explicit focus on maternal morbidity and mortality or intellectual and developmental disabilities. However, proposals for this funding are not limited to these two topics.</p> <p>Individual awards may be made in an amount up to \$100,000 in total costs (direct and indirect) and the maximum project period is 12 months.</p>	<ul style="list-style-type: none"> ● September 1, 2020: Online system opened ● October 1: Deadline for letters of Inquiry (LOI) ● Full proposals are invitation only and are due 40 calendar days after LOI approval ● June 1, 2021: Earliest project start date

Type of Opportunity	Opportunity Description	Key Dates
<p>The Phased Large Awards for Comparative Effectiveness Research – Cycle 3 2020 is a new funding mechanism for PCORI. It seeks proposals for individual-level or cluster randomized controlled trials of significant scale and scope. PCORI anticipates that proposed research projects will require an initial feasibility phase to inform a full-scale or main research study. Continued funding of the second phase to carry out the full-scale study will be contingent upon the achievement of specific milestones and deliverables in the feasibility phase.</p> <p>Proposed studies should compare interventions that already have established evidence of efficacy or are in widespread use.</p>	<p>Investigators may request up to \$2 million in direct costs for a feasibility phase up to 18 months in duration, with up to \$20 million in direct costs for continuation to a full-scale study phase up to five years in duration. Total direct costs for the full proposal should not exceed \$22 million.</p> <p>This funding announcement welcomes applications for trials comparing clinical and/or health systems interventions to address adverse consequences and outcomes relevant to the priority research topics of maternal morbidity and mortality, and individuals with intellectual and developmental disabilities. However, applications are not limited to these two topics and may align more broadly with existing PCORI National Priorities.</p>	<ul style="list-style-type: none"> ● September 29, 2020: Deadline for Letters of Intent ● January 12, 2021: Application deadline ● November 2021: Earliest start date
Research Synthesis and New Technology	<p>This program works through an RFP process to support rigorous reviews of existing evidence on topics identified by healthcare stakeholders. Synthesis products, such as systematic reviews, evidence visualizations, and reports seeking to identify healthcare innovations and new technologies, are made available by PCORI for public use. These products may lend themselves to identifying future needs for new comparative effectiveness research.</p>	Ongoing